616.234.5000

Publications

Grohar Laboratory

Selected Publications

Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn, ME, Manning HC, Grohar PJ. In press. 18F-FLT Positron Emission Tomography (PET) is a pharmacodynamic marker for EWS-FLI1 activity and Ewing sarcoma. Sci Rep 6: 33926.        Article

Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D’Incalci M, von Leuttichau I, Grohar PJ, Berdel WE, Burdach S. In press. Trabectedin followed by irinotecan can stabilize disease in advanced translocation-positive sarcomas. Sarcoma.       Article

Harlow ML, Maloney K, Roland J, Navarro M, Easton MK, Kitchen-Goosen SM, Boguslawski E, Madaj ZB, Johnson BK, Bowman MJ, D’Incalci M, Winn ME, Turner L, Hostetter G, Galmarini C M, Aviles P, Grohar PJ.  In press. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res.       Article

Osgood CL, Maloney KN, Kidd CG, Kitchen-Goosen SM, Segars LE, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith MA, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabin J, Helman LJ, Morís F, Grohar PJ. 2016. Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor. Clin Cancer Res.        PubMed

Caropreso V, Darvishi E, Turbyville TJ, Raynayake R, Grohar PJ, McMahon JB, Woldemichael G. 2016. Englerin A inhibits EWS-FLI1 DNA binding in Ewing sarcoma cells. J Biol Chem.          PubMed

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar PJ, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. 2016. The second European interdisciplinary Ewing sarcoma research summit—A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget.         PubMed

Grohar PJ*, Kim S*, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney KN, Zhu J, O’Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ. 2016. Functional genomic screening reveals splicing of the nascent EWS-FLI1 fusion transcript as a vulnerability in Ewing sarcoma. Cell Rep 14(3):598–610.        PubMed
*Grohar PJ and Kim S contributed equally to this work.

Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D’Incalci MD. 2015. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemother Pharmacol 75(6):1317–1320.        PubMed

Grohar PJ, Segars LE, Yeung C, Mendoza A, Helman LJ. 2014. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.  Clin Cancer Res 20(5):1190–1203.             PubMed
*Featured as a Clin Cancer Res highlight. See Burdach S. 2014. Molecular precision chemotherapy: Overcoming resistance to targeted therapies? 20(5):1064–1066.

Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar PJ, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. 2013. A decade in banking Ewing sarcoma: a report from the Children’s Oncology Group. Front Oncol 3:57.        PubMed

Yeung C, Ngo VN, Grohar PJ, Arnaldez FL, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. 2013. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene 32(47):5429–5438.         PubMed

Grohar PJ, Helman LJ. 2012. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 137(2):216–224.  PubMed

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DC, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. 2011. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103(12):962–978.            PubMed

Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. 2011. Ecteinascidin 743 (ET-743) interferes with the activity of EWS-FLI1 in Ewing’s sarcoma cells.  Neoplasia 13(2):145–153.             PubMed

Wan X, Harkavy B, Shen N, Grohar PJ, Helman LJ. 2007. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940.          PubMed

Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW. 2004. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down Syndrome myeloblasts and leukemia cell lines. Cancer Res 64(2):728–735.        PubMed

Schroeder MC, Hamby JM, Connolly CJC, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH,  Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD. 2001. Soluble 2-substituted amino[2,3-d]pyrimidin-7-yl ureas. Structure-Activity Relationships (SAR) against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 44(12):1915–1926.      Article

Meroueh M, Grohar PJ, Qiu J, SantaLucia J, Scaringe SA, Chow CS. 2000. Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA. Nucleic Acids Res 28(10):2075–2083.        PubMed

Grohar PJ, Chow CS. 1999. A practical synthesis of the modified RNA nucleoside pseudouridine. Tetrahedron Lett 40(11):2049–2052.        Article